Trasylol Study Results Prove Damning For Bayer

Law360, New York (February 21, 2008, 12:00 AM EST) -- The blows keep on coming for Bayer AG, with the full study on the pharmaceutical giant's blood-clotting drug Trasylol lending more weight to preliminary conclusions that the medication leads to kidney failure and an increased chance of death.

On Thursday, the New England Journal of Medicine was expected to publish for the first time the full results of the Bayer-commissioned 2006 Trasylol study, less than a week after a researcher alleged that an estimated 22,000 lives could have been saved if the health care company had...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.